Canaccord raised the firm’s price target on AdaptHealth (AHCO) to $16 from $14 and keeps a Buy rating on the shares. The firm updated its model following Q1 results where EBITDA missed estimates causing a pullback in the shares. Adapt appears to be uniquely positioned in the DME market to gain share, especially if the demand environment for capitated agreements become the preferred method to better serve patients with chronic conditions.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AHCO: